Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

What's next for OxyContin maker Purdue Pharma

Published 09/16/2019, 10:55 PM
Updated 09/16/2019, 10:55 PM
© Reuters. FILE PHOTO: A pharmacist holds a bottle OxyContin made by Purdue Pharma at a pharmacy in Provo, Utah

By Mike Spector

(Reuters) - OxyContin maker Purdue Pharma LP filed for bankruptcy protection after reaching a partial deal to resolve more than 2,600 lawsuits alleging it helped fuel the U.S. opioid crisis.

Supporters of Purdue's plan to restructure under terms of a settlement the company values at more than $10 billion include 24 states and five U.S. territories, as well as lead lawyers for more than 2,000 cities, counties and other plaintiffs suing the company and, in some cases, its controlling Sackler family.

On the other side are two dozen states that remain opposed or uncommitted to the proposed settlement, setting the stage for contentious legal battles over who bears responsibility for a public health crisis that has claimed the lives of nearly 400,000 people between 1999 and 2017, according to the latest U.S. data.

Purdue and the Sacklers have denied allegations in lawsuits alleging they aggressively marketed addictive prescription painkillers while misleading doctors and patients about their abuse and overdose risks.

The following are among the key legal battles ahead, pitting states such as Massachusetts, New York and Connecticut against Purdue and the Sacklers.

PURDUE

*Purdue will soon ask U.S. Bankruptcy Judge Robert Drain to halt all its lawsuits. The company is preparing for states to argue their lawsuits cannot be stopped because their legal actions were brought to enforce public health and safety laws - exempting them from the usual bankruptcy rules that would pause their complaints.

Purdue Chairman Steve Miller in an interview on Sunday night said continued litigation in bankruptcy would deplete the company's assets. Purdue projected spending $263 million this year on legal and professional fees, with nearly half devoted to opioid litigation alone, according to bankruptcy-court records. The legal skirmishes begin with Purdue's first-day bankruptcy hearing on Tuesday in a White Plains, New York, federal court.

*Purdue still faces U.S. Justice Department criminal and civil investigations over its handling of OxyContin. Any financial penalty emerging from those cases could eat into recoveries for cities, counties and states suing the company and the Sacklers. Purdue has responded to subpoenas and other investigative demands from federal prosecutors and is engaged in discussions with U.S. officials to resolve the probes, the company said in bankruptcy-court papers.

THE SACKLERS

*Purdue also said it would seek to stop lawsuits against current and former owners and directors - a veiled reference to the Sacklers. Many states have vowed to continue pursuing the family, and have pushed them to guarantee more money toward a settlement. The Sacklers so far have not budged from a proposal to pay $3 billion over seven years and an additional $1.5 billion or more through an eventual sale of another business they own called Mundipharma.

The Sacklers on Sunday night said they hope opposing states would "shift their focus to the critical resources that the settlement provides to people and problems that need them."

*The Sacklers could attempt to use bankruptcy proceedings to largely shield themselves from future legal exposure and the possible financial liabilities associated with it. Settlements approved in bankruptcy court often come with legal releases. Some states are likely to fight that.

Massachusetts Attorney General Maura Healey on Monday said Purdue's Chapter 11 proceedings "should not be about billionaires looking to use the bankruptcy process as a vehicle to further shield their assets and escape accountability."

New York Attorney General Letitia James has subpoenaed Wall Street banks, Purdue corporate entities and family offices for records related to the Sackler's finances. On Monday, she said her office "will not be deterred in its lawsuit against the Sackler family." On Friday, she highlighted wire transfers made by former Purdue board member Mortimer D.A. Sackler, including some made through Swiss bank accounts. A Sackler representative said the decade-old transfers were legal and appropriate.

© Reuters. FILE PHOTO: A pharmacist holds a bottle OxyContin made by Purdue Pharma at a pharmacy in Provo, Utah

"We will move aggressively in bankruptcy to disclose their hidden fortune and ensure their full wealth is now on the table," Connecticut Attorney General William Tong said in a statement on Monday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.